Prime Medicine, Inc.

PRME

Healthcare|Biotechnology|US

$4.65

+0.20 (+4.49%)

Tangible Book / Share

$0.22

Cash / Share

$0.54

About

Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combines a unique Prime Editor protein—a hybrid composed of a Cas protein and a reverse transcriptase enzyme—with a specialized pegRNA molecule. This pegRNA plays a crucial role by both guiding the Prime Editor to a precise location within the genome and providing the essential template for introducing the desired modification to the target DNA sequence. The company, founded in 2019, maintains its headquarters in Cambridge, Massachusetts.

Stock Price

+11.2%(1Y)

+29.9%

+51.0%

+44.9%

YTD

+34.0%

+31.7%

-38.0%

-69.7%

Pipeline Summary

4 total trials

Phase 1

Phase 2

Phase 3

Phase 4

Active: 1Not Yet Recruiting: 1By Invitation: 1Recruiting: 1

Active Trials (2)

Prescreening Study to Identify Potential Wilson Disease Participants for Gene-Editing Clinical Trial

NCT07226622Wilson Disease

Active

Enrollment: 30 participants

A Study of the Safety and Efficacy of Prime Editing (PM577) in Participants With Wilson Disease (WD)

NCT07748403Wilson Disease

Phase 1Phase 2Recruiting

Enrollment: 42 participants

Key Facts

Market Cap$843.4M

Employees146 (-32% YoY)

CEOAllan Reine

IPO DateOct 20, 2022

Beta2.15

52-Week Range$2.67 – $5.91

Avg Volume3,993,203

ExchangeNASDAQ

Websiteprimemedicine.com

Ownership

Float32.8%

Shares Outstanding181.4M